New $100,000 Rx On Market WASHINGTON (Reuters) – The price of Seattle Genetics Inc’s blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost. Continue reading New $100,000 Rx On Market